Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials) - Crawford, J; Prado, CMM; Johnston, MA (2016)
Curr Oncol Rep